AMGN Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of 13.47% compared to Amgen, Inc.'s net margin of 27.44%. Amgen, Inc.'s return on equity of 102.03% beat Gilead Sciences, Inc.'s return on equity of 41.72%.

Amgen, Inc. has a consensus price target of $350.03, signalling downside risk potential of -3.07%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $157.43 which suggests that it could grow by 9.02%. Given that Gilead Sciences, Inc. has higher upside potential than Amgen, Inc., analysts believe Gilead Sciences, Inc. is more attractive than Amgen, Inc..

Amgen, Inc. has a beta of 0.451, which suggesting that the stock is 54.886% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.44%.

Amgen, Inc. has a quarterly dividend of $2.52 per share corresponding to a yield of 2.68%. Gilead Sciences, Inc. offers a yield of 2.21% to investors and pays a quarterly dividend of $0.82 per share. Amgen, Inc. pays 66.92% of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Amgen, Inc. quarterly revenues are $9.9B, which are larger than Gilead Sciences, Inc. quarterly revenues of $8B. Amgen, Inc.'s net income of $1.3B is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Amgen, Inc.'s price-to-earnings ratio is 25.37x while Gilead Sciences, Inc.'s PE ratio is 21.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen, Inc. is 5.32x versus 6.16x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 13.47% compared to Amgen, Inc.'s net margin of 20.83%. Amgen, Inc.'s return on equity of 102.03% beat Johnson & Johnson's return on equity of 34.46%.

Amgen, Inc. has a consensus price target of $350.03, signalling downside risk potential of -3.07%. On the other hand Johnson & Johnson has an analysts' consensus of $240.38 which suggests that it could grow by 0.95%. Given that Johnson & Johnson has higher upside potential than Amgen, Inc., analysts believe Johnson & Johnson is more attractive than Amgen, Inc..

Amgen, Inc. has a beta of 0.451, which suggesting that the stock is 54.886% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.338, suggesting its less volatile than the S&P 500 by 66.17%.

Amgen, Inc. has a quarterly dividend of $2.52 per share corresponding to a yield of 2.68%. Johnson & Johnson offers a yield of 2.18% to investors and pays a quarterly dividend of $1.30 per share. Amgen, Inc. pays 66.92% of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Amgen, Inc. quarterly revenues are $9.9B, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Amgen, Inc.'s net income of $1.3B is lower than Johnson & Johnson's net income of $5.1B. Notably, Amgen, Inc.'s price-to-earnings ratio is 25.37x while Johnson & Johnson's PE ratio is 21.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen, Inc. is 5.32x versus 6.14x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 13.47% compared to Amgen, Inc.'s net margin of 34.4%. Amgen, Inc.'s return on equity of 102.03% beat Eli Lilly & Co.'s return on equity of 104.39%.

Amgen, Inc. has a consensus price target of $350.03, signalling downside risk potential of -3.07%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.34 which suggests that it could grow by 29.99%. Given that Eli Lilly & Co. has higher upside potential than Amgen, Inc., analysts believe Eli Lilly & Co. is more attractive than Amgen, Inc..

Amgen, Inc. has a beta of 0.451, which suggesting that the stock is 54.886% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.355%.

Amgen, Inc. has a quarterly dividend of $2.52 per share corresponding to a yield of 2.68%. Eli Lilly & Co. offers a yield of 0.67% to investors and pays a quarterly dividend of $1.73 per share. Amgen, Inc. pays 66.92% of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Amgen, Inc. quarterly revenues are $9.9B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Amgen, Inc.'s net income of $1.3B is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Amgen, Inc.'s price-to-earnings ratio is 25.37x while Eli Lilly & Co.'s PE ratio is 41.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen, Inc. is 5.32x versus 13.00x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 13.47% compared to Amgen, Inc.'s net margin of 21.74%. Amgen, Inc.'s return on equity of 102.03% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Amgen, Inc. has a consensus price target of $350.03, signalling downside risk potential of -3.07%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $872.85 which suggests that it could grow by 15.32%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Amgen, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Amgen, Inc..

Amgen, Inc. has a beta of 0.451, which suggesting that the stock is 54.886% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.484%.

Amgen, Inc. has a quarterly dividend of $2.52 per share corresponding to a yield of 2.68%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.94 per share. Amgen, Inc. pays 66.92% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Amgen, Inc. quarterly revenues are $9.9B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Amgen, Inc.'s net income of $1.3B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Amgen, Inc.'s price-to-earnings ratio is 25.37x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen, Inc. is 5.32x versus 5.73x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.